NSABP Biological Specimen Banks

描述(由申请人提供)：在过去的50年里，NSABP随机选择了100,000多名被诊断为乳腺癌或结直肠癌的患者进行临床试验。基于在这些试验中测试的治疗方式的多个进化步骤所获得的增量收益，患者结果总体上已获得显著改善。然而，这种方法也意味着对一些没有从各种干预措施中受益的患者出现了严重的过度治疗，这些干预措施现在已经成为添加新药物的传统治疗的一部分。为了实现更个性化的治疗目标，需要开发可靠的预后和预测性测试。由于伦理原因，一旦证明了新方案的有效性，就不能再次进行试验，因此NSABP进行的历史试验的存档肿瘤组织块为试图开发此类测试的研究人员提供了重要的资源。NSABP病理组织库分部的NSABP生物组织库存储了来自8.7万多名患者的肿瘤组织样本，是科学界的开放资源，为新的预后或预测性测试的开发和临床验证提供组织。组织标本根据科学价值提供给学术界和私营部门的研究人员。私营部门与世行合作开发的基于多基因表达的预后测试(OncotypeDX)已成为美国激素受体阳性结节阴性乳腺癌临床治疗的标准。福尔马林固定的石蜡包埋块的全基因组基因表达分析和突变分析方法的内部开发和/或优化方法进一步提高了NSABP Biospecimen Bank的价值。

DESCRIPTION (provided by applicant): The NSABP has randomized more than 100,000 patients with diagnoses of breast or colorectal cancers into clinical trials during the past 50 years. Based on incremental benefit achieved through multiple evolutionary steps of treatment modalities tested in those trials, significant improvement in patient outcomes has been achieved overall. However, this approach also means that there has been significant over-treatment of some patients who did not benefit from the various interventions, which now have become part of legacy treatments to which newer agents are added. Development of reliable prognostic and predictive tests is required to deliver the goal of more personalized treatment. Since, for ethical reasons, trials cannot be conducted again once the efficacy of newer regimens is demonstrated, archived tumor tissue blocks from historical trials conducted by the NSABP provide an essential resource to investigators who are trying to develop such tests. The NSABP Biospecimen Bank at the NSABP Division of Pathology Tissue Bank houses tumor-tissue specimens from more than 87,000 patients and serves as an open resource to the scientific community to provide tissues for development and clinical validation of new prognostic or predictive tests. Tissue specimens are provided to investigators from both academia and the private sector on the basis of scientific merit. A multi-gene expression based prognostic test (OncotypeDx) developed in a collaboration between the private sector and the bank has become a standard in clinical management of hormone receptor positive node negative breast cancer in the United States. In-house development and/or optimization of methods for whole-genome gene-expression analyses and mutation profiling of formalin-fixed, paraffin-embedded blocks further enhances the value of the NSABP Biospecimen Bank.